BRIEF-Acrivon Therapeutics Reports Positive Endometrial Cancer Data From Ongoing Acr-368 Registrational Intent Phase 2 Study At Esmo

Reuters
2024-09-14

Sept 14 (Reuters) - Acrivon Therapeutics Inc :

* ACRIVON THERAPEUTICS REPORTS POSITIVE ENDOMETRIAL CANCER DATA FROM ONGOING ACR-368 REGISTRATIONAL INTENT PHASE 2 STUDY AT ESMO, ADVANCEMENT OF ACR-2316 INTO CLINIC AHEAD OF TIMELINES, AND PROGRESS ON ITS AP3 INTERACTOME FOR PROPRIETARY DATA ANALYSIS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10